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Abstract
Background: Despite the high prevalence of seizure, epilepsy and abnormal electroencephalograms in individuals
with autism spectrum disorder (ASD), there is little information regarding the relative effectiveness of treatments
for seizures in the ASD population. In order to determine the effectiveness of traditional and non-traditional
treatments for improving seizures and influencing other clinical factor relevant to ASD, we developed a
comprehensive on-line seizure survey.
Methods: Announcements (by email and websites) by ASD support groups asked parents of children with ASD to
complete the on-line surveys. Survey responders choose one of two surveys to complete: a survey about
treatments for individuals with ASD and clinical or subclinical seizures or abnormal electroencephalograms, or a
control survey for individuals with ASD without clinical or subclinical seizures or abnormal electroencephalograms.
Survey responders rated the perceived effect of traditional antiepileptic drug (AED), non-AED seizure treatments
and non-traditional ASD treatments on seizures and other clinical factors (sleep, communication, behavior,
attention and mood), and listed up to three treatment side effects.
Results: Responses were obtained concerning 733 children with seizures and 290 controls. In general, AEDs were
perceived to improve seizures but worsened other clinical factors for children with clinical seizure. Valproic acid,
lamotrigine, levetiracetam and ethosuximide were perceived to improve seizures the most and worsen other
clinical factors the least out of all AEDs in children with clinical seizures. Traditional non-AED seizure and non-
traditional treatments, as a group, were perceived to improve other clinical factors and seizures but the perceived
improvement in seizures was significantly less than that reported for AEDs. Certain traditional non-AED treatments,
particularly the ketogenic diet, were perceived to improve both seizures and other clinical factors.
For ASD individuals with reported subclinical seizures, other clinical factors were reported to be worsened by AEDs
and improved by non-AED traditional seizure and non-traditional treatments.
The rate of side effects was reportedly higher for AEDs compared to traditional non-AED treatments.
Conclusion: Although this survey-based method only provides information regarding parental perceptions of
effectiveness, this information may be helpful for selecting seizure treatments in individuals with ASD.
Background
Individuals with autism spectrum disorder (ASD) have a
3 to 22-fold increase in the risk of developing epilepsy
as compared to typically developing individuals and up
to 25% of individuals with ASD will experience a clinical
seizures at some point in their life [1,2]. However, the
relationship between epilepsy and ASD is complex [3].
For example, a significant number of individuals with
ASD manifest epileptiform abnormalities on electroen-
cephalograph (EEG) despite a lack of clinical seizures,
and many of these epileptiform abnormalities do not
meet criteria for electrographic seizures [4].
Despite the high prevalence of seizure, epilepsy and
abnormal EEGs in individuals with ASD, there is little
information regarding the relative effectiveness of treat-
ments for epilepsy, seizure or subclinical epileptiform
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believe that specific antiepileptic drugs (AEDs) might be
effective for individuals with ASD. For example, ASD is
associated with cortical hyperexcitability, potentially due
to deficits in cortical inhibitory circuits [5]. This sug-
gests that AEDs that enhance gamma-aminobutyric acid
pathways might be relatively better treatments for indi-
viduals with ASD. Additionally, the non-seizure effects
of AEDs, such as mood regulation, could be particularly
helpful in individuals with ASD [6]. Finally, older AEDs
tend to have higher rates of adverse effects, particularly
with respect to attention, mood and cognition [7,8].
Since individuals with ASD already have problems with
attention, mood and cognition, prescribing an AED with
such adverse effects might result in poor overall func-
tion even if seizures are controlled. Thus, the first pur-
pose of this study was to determine whether there are
specific AEDs that are more appropriate to use in chil-
dren with ASD.
Many individuals with ASD use non-traditional treat-
ments, such as special diets and nutritional supplements
[9,10]. Some non-traditional treatments may help with
the frequency and severity of seizures since many of
these treatments target inflammation and oxidative
stress [9,11,12], two pathological processes believed to
be involved in the pathogenesis and propagation of sei-
zures [13-15]. Thus, a second purpose of this study was
to determine whether there are any non-traditional
treatments that may be effective for treating seizures in
children with ASD.
To shed light on the ability of treatments used in ASD
to affect seizures and other important clinical character-
istics associated with ASD, we developed an on-line sei-
zure survey to investigate parental perceptions about the
effect of treatments for their children with ASD on sei-
zures. This survey included questions on seizure charac-
teristics, comorbid medical conditions, the effect of
traditional AED and non-AED seizure treatments and
non-traditional ASD treatments on seizures, behavior
and cognition, and adverse effects of treatments. The
survey was designed to keep the completion time to less
than 30 minutes. Although parental reports have their
limitations, seizure treatment is often an individualized
trial-and-error process, thus, it was the third purpose of
this study to provide data that may help clinicians select
treatments which are more likely to reduce seizures
with minimal side-effects, and to help increase the
awareness of treatment side-effects.
Methods
Institutional Review Board Approval
This study was conducted in accordance with the
Declaration of Helsinki and the Institutional Review
Board. Since the survey was anonymous and did not
contain any unique indentifying information or pro-
tected health information, the study qualified for cate-
gory 2 exempt status according to 45 CFR 46.101(b).
Information regarding Institutional Review Board
approval and contact information was provided on the
first page of the survey.
Survey Development
The first and last authors drafted an invitation letter and
survey. The survey was designed using the principles
outlined by Keenan [16] as implemented with the Sur-
veyMethods, Inc. website software (http://www.Survey-
Methods.com). Straightforward unambiguous non-open-
ended questions were used when possible. The survey
was designed to be comprehensive in the variety of pos-
sible responses so as to eliminate the need for free text
entry. In order to reduce perceived bias of the survey
for a specific type of treatment, the survey was designed
to include a wide range to treatments commonly used
in the treatment of ASD, both traditional treatments for
seizures as well as non-traditional treatments.
The first page of the survey provided the responder
with basic information regarding the purpose of the sur-
vey, a statement regarding the host institution and regu-
latory approval from the institution and an approximate
completion time. The second page of the survey pro-
vided the responder with more specific information
regarding the structure of the survey, the correct man-
ner in which to respond to specific questions and con-
tact information for the principal investigator if the
responder wanted more information or had any ques-
tions. The survey did not record any identifying infor-
mation of the responder nor did it ask for any protected
health information identifiers. The survey was designed
to be easy to answer with validation checks for each
response and used skipping logic to make the survey
easy and efficient to answer. Except where noted,
answers were providing by multiple checkbox, rating
scales, yes/no questions or specific fill in the blank ques-
tions. Very few open-ended questions or questions that
required free text entry were used.
Some basic information was collected about each child
with ASD including current age, gender, spectrum diag-
nosis and developmental profile, commonly associated
medical conditions (a text box was provided for entering
other medical conditions not listed), and the practi-
tioners that manage the child’s medical and develop-
mental disorders.
Specific information regarding seizures was also quer-
ied. Responders indicated practitioners that managed or
rule-out the seizure disorder and the type of test used
to diagnose or rule out seizures. Responders indicated
whether the individual with ASD had any of the follow-
ing seizure types: generalized, partial complex, absence,
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epileptiform discharges, Lenox-Gastaut syndrome and/
or infantile spasms. These choices were provided in a
checkbox fashion so that multiple seizure types could be
indicated. Next to each common seizure type was a
detailed description of the seizure type to help the
responder select the correct seizure type. There was also
ac h e c k b o xf o rt h er e s p o n d e rt op l a c eo t h e rs e i z u r e
types if the seizure types listed were not sufficient.
Other information regarding seizures (including age of
onset and age of resolution of seizures if the seizures
resolved) was also collected.
Following collection of this basic descriptive informa-
tion, the respondents were asked to indicate if their
child had been treated with a wide range of treatments.
Information for each treatment was collected in a
sequential manner. For each treatment, a page would
appear with a yes/no question asking the respondent
whether a specific treatment had been used. Both gen-
eric and brand names, inclusive of all known brand
names, were included in the question. If the respondent
answered ‘yes’ they were directed to a page where they
could rate the perceived effect of the treatment and list
the adverse effects. If they answered ‘no’ the respondent
was questioned about the next treatment. This skip
logic in the software eliminated the need for the respon-
dent to understand which questions needed to be
answered and which needed to be skipped, thereby elim-
inating potential confusion that can occur with condi-
tional questions in surveys. Additional pages asked the
respondent if their child was treated for seizures with a
treatment that was not mentioned. If the respondent
answered ‘yes’, a page appeared which included a text
box to enter the information regarding the treatment
along with a page to rate the perceived effect of the
treatment and any adverse effects.
For each treatment, the respondent was asked to rate the
perceived effect of the treatment on seizures, sleep, recep-
tive and expressive language, verbal and non-verbal com-
munication, stereotyped/repetitive movements, rigidity,
hyperactivity, attention and mood. A seven point scale was
used that ranged from a substantial negative effect, a mod-
erate negative effect, to a mild negative effect to no effect
to a mild positive effect, a moderate positive effect, to a
substantial positive effect. All ratings for this complex
multi-dimensional construct of the perceived treatment
effect were included on the same page to facilitate the
respondent’s use of the same psychometric scale. The rat-
ing scale was designed to be symmetric (i.e., same number
of positive and negative ratings) in order to minimize
response bias. Three sets of text boxes were provided to
enter any adverse effect, the severity of the adverse effect
and the frequency of the adverse effect. This allowed the
respondent to enter up to three adverse effects.
Survey Validation
The survey and participant invitation letter were devel-
oped with the advice of a wide variety of experts with
experience in the treatment of children with ASD. A
copy of the invitation letter and a link to the initial sur-
vey were sent to participants of the Elias Tembenis Sei-
zures Think Tank (which took place at the AutismOne
Meeting in Chicago in May of 2009) approximately one
month before the think tank. The participants of this
think talk represented a wide variety of practitioners
who treat ASD (See See Additional file 1, Appendix A).
Participants were asked to complete the survey as many
times as necessary to get familiar with the survey. Dur-
ing the day-long think tank the first and last authors led
a discussion querying the participants on their opinion
regarding the specific information about the children
with ASD and seizures, the treatments that should be
surveyed and the specific effect of each treatment that
should be asked as well as the wording of the survey.
Over the weeks following the survey, changes were
made to the initial survey and invitation letter as a result
o ft h es u g g e s t i o n so ft h em e m b e r so ft h et h i n kt a n k .
Participants were again asked to complete the survey
and provide additional comments by email. The survey
was again modified and the participants were again
asked to review the survey. After no further suggestions
were made, the first and last authors recruited volunteer
parents with children affected by ASD and seizures to
review the survey and invitation letter. The survey and
invitation letter were sent to these volunteers and their
suggestions were integrated into the survey and letter
and the modified survey and letter were again sent out
for review to these volunteers. After no more significant
comments were received, the final survey and invitation
letter were prepared.
Treatments Surveyed
The expert group decided on including the following
treatments for the survey. Traditional seizure treatments
included valproic acid, phenytoin, lamotrigine, levetira-
cetam, caramazapine, topiramate, oxcarbazepine, pyri-
doxine, clonazepam, phenobarbitol, zonisamide,
gabapentin, felbamate, ethosuximide, tigabine, primi-
done, vigabatrin, neurofeedback, ketogenic diet, Atkin’s
or modified Atkin’s diet, steroids, vagus nerve stimula-
tion, surgery, intravenous immunoglobulin, transcranial
magnetic stimulation/direct current stimulation. Non-
traditional treatments included gluten free casein free
diet, specific carbohydrate diet, hyperbaric oxygen ther-
apy, 5-Hydroxytryptophan, gamma-aminobutyric acid,
dimethylglycine, taurine, chelation therapy, co-enzyme
Q10, B6, gluatathione, magnesium, B12, L-carnitine/
Acetyl-L-carnitine, L-carnosine, minocycline, bacopa,
actos, and spironolactone.
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ments at the same time, information regarding response
to specific treatment was queried individually for each
treatment. This assumes that each treatment is having
an influence independent of the other treatments. The
authors and the expert group believe this was a neces-
sary limitation since asking about each combination of
treatments would create a questionnaire that would be
prohibitively long and complex. In addition, it is likely
that the number of respondents with experience with
specific treatment combinations would be prohibitively
small for a valid analysis. From a practical point of view,
most practitioners usually start and/or stop treatments
independent each other so that the clinical effect (and
adverse effect) can be determined for the specific
treatment.
Questions Included in the Survey But Not Addressed In
This Study
In addition to questions regarding seizures, the survey
contained a small section in the beginning that asked
about the effect of allergies and season on seizures and
behavior. Additional questions within the survey also
asked about over- or under-reactivity to external stimuli
and the effect of treatments on such reactivity. These
aspects of the survey are not addressed in this
manuscript.
Control Survey
In order to determine a baseline for the data collected
on children with ASD and seizures, a control survey was
developed to gather information regarding children with
ASD without seizures (henceforth described as the con-
trol survey). This control survey contained all of the
questions that the seizure survey contained except for
specific questions about seizures (e.g., “What type of sei-
zures has your child been diagnosed with?”). All treat-
ments in the seizure survey were included in the control
survey but a rating for the effect of the treatment on
seizures was not included. Questions were included
regarding whether the child had been evaluated for sei-
zure, what type of practitioner evaluated the child and
what test, if any, had been done to rule-out seizures.
Recruitment
An invitation letter (See See Additional file 1, Appendix
B) for the on-line survey was posted on the website and
in email newsletters of the Autism Research Institute
(ARI) and approximately 30 local and national ASD sup-
port groups for parents of individuals with ASD. The
non-ARI support groups included Autism Speaks, sev-
eral local chapters of the Autism Society of America
and ARC and other local support groups for families of
autism. The letter specifically asked parents of children
with ASD both with and without seizures to follow one
of two web links depending on whether or not their
child had clinical seizures, subclinical epileptiform dis-
charges or seizure-like activity. These web links acti-
vated different surveys located on the SurveyMethods,
Inc. website (http://www.SurveyMethods.com). Identical
letters were used for ARI and non-ARI websites except
that the links referred to surveys that stored responses
in different databases. This allowed responses to exact
same seizure or control survey questions to be stored in
different databases depending on whether the respon-
dent had followed the link from the ARI or non-ARI
webpage.
Survey Response Reduction
The frequencies of specific genetic conditions were very
low so all responses for specific genetic disease were
included as a general genetic condition response. Treat-
m e n t sw i t hl e s st h a n2 0t o t a lr e s p o n s e sw e r ee x c l u d e d
from all analyses. These included surgery, transcranial
magnetic stimulation/direct current stimulation, tiga-
bine, primidone, vigabatrin, neurofeedback, minocycline,
bacopa, actos, and spironolactone. Treatments with less
than 20 responses for the subclinical seizure group were
excluded from the subclinical seizure treatment analysis.
These included ethosuximide, phenytoin, clonazepam,
gabapentin, zonisamide, felbamate, phenobarbitol, vagus
nerve stimulator, intravenous immunoglobulin, hyperba-
ric oxygen therapy, dimethylglycine, gamma-aminobuty-
ric acid, and specific carbohydrate diet. For the
subclinical seizure treatment analysis, responses for the
ketogenic diet and Atkin’s or modified Atkin’s diet were
combined because of their similarity in order to prevent
elimination due to too few responses.
Statistical Analysis
Chi-squares were used to analyze bivariate variables. To
mitigate the effect of multiple comparisons, for each set
of comparisons made, the Bonferroni correction was cal-
culated to correct the alpha cutoff. The caption of each
table explains the appropriate Bonferroni correction.
Ratings were converted into an ordinal scale ranging
from 1 to 7 for analysis: substantial negative effect (1), a
moderate negative effect (2), a mild negative effect (3),
no effect (4), a mild positive effect (5), a moderate posi-
tive effect (6), and a substantial positive effect (7).
Although the response scale was ordinal, the response
distribution was found to be normally distributed allow-
ing the use of parametric analyses for treatment ratings.
Comparing every treatment to every other treatment
would result in a very large number of comparisons
(>500), thereby considerably increasing the probability
of a type I error. To reduce the number of comparisons
we investigated whether multiple treatments could be
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pattern of ratings for seizures and other clinical factors
(i.e., sleep, communication, behavior, attention, mood)
and then compared the ratings from each treatment
cluster to other treatment clusters.
F o rt h ec l u s t e ra n a l y s i s ,s e i z u r et y p e sw e r ed i v i d e d
into two broad categories: clinical (generalized, partial
complex, absence) and subclinical (typical and atypical
Landau-Kleffner syndrome, subclinical epileptiform dis-
charges). Lenox-Gastaut syndrome and infantile spasms
were not considered in this manuscript. For the cluster
analysis, two summary scales were calculated to reduce
the number of rating scales: receptive and expressive
language and verbal and non-verbal communication rat-
ings were averaged to create a rating called communica-
tion and stereotyped/repetitive movements, rigidity and
hyperactivity ratings were averaged to create a rating
called behavior. For subclinical seizures we did not
include the seizure ratings in the cluster analysis as the
primary manifestations of subclinical seizures are other
clinical factors and seizures are not reliably detected in
individuals with subclinical seizures.
Cluster analysis was conducted using Ward’st e c h n i -
q u e[ 1 7 ] .T h eW a r d ’s technique defines the distance
between treatments in terms of the between cluster
variability to the within cluster variability. The Ward’s
technique is a hierarchical analysis that starts with n
clusters, one for each treatment, and then at each step
groups the most similar treatments into clusters. This
procedure continues until there is one cluster containing
all respondents. By examining the dendogram and sev-
eral statistics (pseudo F and t), a judgment is made
about the number of clusters [18].
The ratings of treatments within each cluster were
compared to the rating from other clusters using a
mixed-model analysis-of-variance (ANOVA) with two
fixed-effects: cluster and seizure type (generalized, par-
tial complex, absence for clinical seizures and Landau-
Kleffner syndrome, atypical Landau-Kleffner syndrome,
subclinical epileptiform discharges for subclinical sei-
zures), and the interaction between these factors. The
ANOVA was calculated using the ‘glimmix’ procedure
of SAS 9.1 (SAS Institute Inc., Cary, NC) with respon-
dent and seizure type as a random variable. Seizure type
and the interaction were not significant in any analysis.
Statistical values for the analysis of variables are pre-
sented in supplementary tables (See Additional file 2)
along with the calculation for the Bonferroni correction.
The statistical values for the seizure type and the inter-
action effects were not included in the tables since they
were not significant. For selected clusters, individual
treatments were compared using a similar ANOVA.
Planned contrasts were used to compare ratings.
Planned contrasts were calculated using the ‘estimate’
command in SAS for the ‘glimmix’ procedure. The pro-
cedure uses both the fixed-effects and random-effects
matrices to construct a matrix with an approximate t
distribution. The unadjusted t-values and p-values are
presented and the Bonferroni correction was used to
calculate the appropriate alpha levels for each set of
comparisons. Statistical values for the cluster or treat-
ment effects of the analysis are presented in supplemen-
tary tables (See Additional file 2), along with the results
of the contrasts.
Results
Characteristics of seizure and control groups
Overall, 1023 responders completed the surveys, with
733 responses concerning children with ASD and clini-
cal seizures, subclinical epileptiform discharges or sei-
zure-like activity and 290 control responses. Seven
invalid responses were deleted.
In both the seizures and control surveys, 77% of the
children were male. This proportion was not signifi-
cantly different across control and seizure survey
groups. Children in the control survey were significantly
younger [9y 5m (SD 5y 11m)] than the children in the
seizure survey [13y 4m (SD 6y 8m); t = 9.0, p < 0.0001];
this may relate to some individuals only developing sei-
zures later in life. Table 1 outlines the practitioners who
regularly managed children reported in the control and
seizures surveys. Overall, the majority of children were
managed, at least in part, by a pediatrician. The second
most prevalent practitioner was a child neurologist,
although this proportion was significantly higher for the
children with seizures as compared to the controls.
One-third of children were managed, at least in part, by
Table 1 Practitioners who regularly manages the child
with ASD
Practitioner Overall Controls Seizures
Pediatrician 66% 59% 69%
ns
Child Neurologist 49% 23% 60%
†
Doctor affiliated with Defeat Autism
Now!
33% 29% 34%
ns
Psychiatrist 20% 20% 20%
ns
Family practitioner 15% 14% 15%
ns
General practitioner 16% 10% 18%
ns
Adult Neurologist 11% 0% 15%
†
Holistic Medicine 10% 9% 10%
ns
Integrative Medicine 5% 5% 5%
ns
‡p < = 0.001; †p < = 0.0001
For each practitioner listed, statistical comparisons were made between the
individuals reported to have seizures and the individuals reported not to have
seizures (control group). Superscript after the seizure percentage indicates
whether the proportions are different between the two groups. There are 9
practitioners resulting in 9 comparisons. The Bonferroni correction results in
an alpha of 0.05/9 = 0.0056, so we have set the alpha to p < = 0.001 to be
conservative.
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tional program of the ARI) and one-fifth of children
were managed, at least in part, by a psychiatrist. Chil-
dren were managed by family and general practitioners,
at least in part, 15% and 14% of the time, respectively.
Children were managed, at least in part, by holistic and
integrative medicine practitioners 10% and 5% of the
time, respectively. An adult neurologist managed, at
least in part, 11% of children but this proportion was
significantly higher for the seizures group as compared
to the control group. Indeed, almost none of the chil-
dren in the control group were managed by an adult
neurologist. These proportions were not different for
those who responded to the ARI invitation as compared
to the support group invitations.
Fifty-three respondents reported that the child had
both clinical and subclinical seizures. These responses
were included in both the clinical and subclinical seizure
groups. This resulted in 548 responses about children
with clinical seizures and 144 responses about children
with subclinical seizures. Males made up 76% and 78%
of the clinical seizures and subclinical seizure groups,
respectively, with no significant difference in these pro-
portions across groups. The average age of the child at
the time the survey was 13y 5m (SD 7y 1m) and 12y 1m
(SD 6y 6m) for children with clinical and subclinical sei-
zures, respectively. This age difference was not statisti-
cally significant. Seizures resolved in 15.8% and 16.0% of
the children reported to have clinical and subclinical sei-
zures, respectively. In children with resolved seizures,
clinical and subclinical seizures were reported to start at
5y 7m (SD 5y 11m) and 5y 11m (SD 6y 5m), respec-
tively, and resolve at 9y 7m (SD 6y 7m) and 10y 11m
(SD 6y 6m), respectively. These ages were not signifi-
cantly different between groups. For children with sei-
zures that did not resolve, seizures were reported to
s t a r ta tas l i g h t l yy o u n g e ra g e( t=3 . 7 0 ,p<0 . 0 0 1 )f o r
those reported to have subclinical seizures [5y 11m (SD
4y 4m)] as compared those reported to have clinical sei-
zures [6y 2m (SD 5y 7m)]. The length of time a child
was affected by seizures was 4y 0m (4y 3m) and 5y 0m
(4y 0m) for those whose seizures had resolved for clini-
cal and subclinical seizures, respectively and the length
of time a child was affected by seizures was 7y 2m (6y
7m) and 7y 3m (6y 2m) for those whose seizures had
not resolved for clinical and subclinical seizures, respec-
tively. The length of time was not significantly different
between the clinical and subclinical seizures groups for
children whose seizures were reported resolved or
reported not to resolve.
Table 2 outlines the type of practitioner who diag-
nosed and managed the seizures in children reported in
the survey organized by practitioner prevalence as calcu-
lated by the weighted average of the three groups. For
the control survey this question pertained to the practi-
tioner who performed an evaluation to rule-out clinical
or subclinical seizures. Since some controls might not
have been evaluated for seizures, an additional option
was included in the control survey to indicate that no
evaluation had been performed. A child neurologist
most often diagnosed and managed seizures, on average,
with the percentage of children with clinical or subclini-
cal seizures being diagnosed and managed by a child
neurologist significantly more often than controls. In
fact, the great majority of children with clinical or sub-
clinical seizures were diagnosed and managed by a child
neurologist as compared to other practitioners. Pediatri-
cians were the 2
nd most likely practitioner to diagnose
and manage seizures but this was primarily due to the
high rate of control children that were evaluated by
pediatricians. In fact, a pediatrician evaluated the great
majority of control children. Doctors affiliated with
Defeat Autism Now! were the 3
rd most likely practi-
tioners reported, on average, to diagnose and manage
seizures. Doctors affiliated with Defeat Autism Now!
were less likely to diagnosed and manage seizures in
children with clinical seizures as compared to children
with subclinical seizures or control children. Adult neu-
rologists were the 4
th most likely practitioners, on aver-
age, to diagnose and manage seizures but this was
primarily due to the significantly higher rate of children
with clinical or subclinical seizures being managed by
an adult neurologist. Psychiatrists and family medicine,
holistic medicine and integrative medicine practitioners
were the 5
th,6
th,7
th and 8
th most likely practitioners to
diagnose and manage seizures. These practitioners were
more likely to evaluate control children than diagnose
and manage children with clinical or subclinical sei-
zures. General practitioners managed very few children
reported by the respondents of this survey.
Table 3 outlines the tests used to diagnose or rule-out
seizures in children with ASD .T h ed i a g n o s t i ct e s t sa r e
organized by the overall percentage of children who
received such tests as calculated by the weighted average
of the three groups. A routine EEG was the most fre-
quently used diagnostic test with significantly more chil-
dren with clinical and/or subclinical seizures having had
a routine EEG as compared to controls. The overnight
EEG was the second most widely used diagnostic test
with significantly more children with clinical and/or
subclinical seizures having had an overnight EEG as
compared to controls. In addition, significantly more
children with subclinical seizures received an overnight
EEG as compared to children with clinical seizures. A
minority of children diagnosed with clinical and/or sub-
clinical seizures were diagnosed without a diagnostic
test, while just over half of the controls did not receive
a diagnostic test - a percentage similar to the proportion
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ambulatory EEG was the third most often used test for
all groups, although it was used significantly less in the
control group. Magnetoencephalography, positron emis-
sion tomography and single photon emission computed
tomography were used in a small percentage of the con-
trol group and in a minority of the clinical and subclini-
cal seizure groups.
Table 4 outlines the reported spectrum diagnosis for
the three seizure groups. The majority of children were
reported to be diagnosed with Autism Disorder with
this diagnosis reported in a higher percentage of chil-
dren diagnosed with seizure or subclinical seizures as
compared to controls. The second most common devel-
opmental diagnosis was pervasive developmental disor-
der-not otherwise specified (PDD-NOS) with the
proportion of children diagnosed with PDD-NOS similar
across all groups. Fewest children were diagnosed with
Asperger syndrome for all groups with a significantly
smaller proportion of children diagnosed with this
spectrum disorder in the two seizure groups as com-
pared to the control group. Both seizure groups were
more likely to be reported to have developmental
regression as compared to the control group but other
developmental profiles were similar across all groups.
Table 5 outlines the reported medical characteristics by
seizure group. The clinical seizure group had propor-
tionally more individuals with mental retardation as
compared to the control group but all other medical
disorders were similar across both seizure and control
groups.
Prevalence of traditional treatments in seizure and
control groups
Table 6 presents the reported usage prevalence of tradi-
tional treatments for seizures organized by AED and
non-AED treatments and sorted by the overall preva-
lence within each treatment category. Overall, AED
treatments were reportedly used more often in both the
clinical and subclinical seizure groups as compared to
Table 2 Practitioners who evaluated and managed ASD individual for seizures
Practitioner Overall Controls Clinical Seizures Subclinical Seizures
Child Neurologist 58.4% 30% 71%
† 76%
†,ns
Adult Neurologist 12.7% 2% 19%
† 12%
†,ns
Doctor affiliated with Defeat Autism Now! 10.9% 2% 13%
† 21%
†,ns
Psychiatrist 9.3% 2% 5%
† 4%
†,ns
Pediatrician 7.2% 4% 9%
† 9%
†,ns
Family practitioner 3.7% 1% 3%
† 3%
†,ns
Holistic Medicine 3.0% 0% 4%
† 5%
†,ns
General practitioner 1% 1% 1%
† 1%
‡,ns
Integrative Medicine 0.7% 0% 1%
ns 1%
ns,ns
No Evaluation 60%
‡p < = 0.001; †p < = 0.0001
For each practitioner listed, statistical comparisons were made between the clinical seizure group and the control group (superscript after the clinical seizure
percentage), the subclinical seizure group and the control group (1st superscript after the subclinical seizure percentage) and between the clinical and subclinical
seizure group (2nd superscript after the subclinical seizure percentage). There are 9 practitioners and 3 comparisons for each practitioner resulting in 27
comparisons. The Bonferroni correction results in an alpha of 0.05/27 = 0.0019, so we have set the alpha to p < = 0.001 to be conservative. Note that the
seizures groups were not given the option of answering no evaluation so percentages are not reported.
Table 3 Tests used to diagnose or rule-out seizures by seizure group
Diagnostic Test Overall Controls Clinical Seizures Subclinical Seizures
Routine electroencephalogram 61.8% 28% 78%
† 68%
†,ns
Overnight electroencephalogram 34.6% 10% 41%
† 60%
†,†
No Test 27.5% 56% 17%
† 10%
†,ns
Ambulatory electroencephalogram 17.6% 3% 21%
† 34%
†,‡
Magnetoencephalography 3.4% 1% 4%
ns 6%
‡,ns
Positron emission tomography 5.1% 1% 6%
‡ 10%
†,ns
Single photon emission computed tomography 5.5% 1% 6%
‡ 13%
†,ns
‡p < = 0.001; †p < = 0.0001
For each diagnostic test listed, statistical comparisons were made between the clinical seizure group and the control group (superscript after the clinical seizure
percentage), the subclinical seizure group and the control group (1
st superscript after the subclinical seizure percentage) and between the clinical and subclinical
seizure group (2
nd superscript after the subclinical seizure percentage). Since there are 7 diagnostic tests and 3 comparisons for each diagnostic test resulting in
21 comparisons. The Bonferroni correction results in an alpha of 0.05/21 = 0.0023, so we have set the alpha to p < = 0.001 to be conservative.
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usage prevalence was not significantly different for the
control and clinical seizure groups. Valproic acid was
the most commonly used AED for all groups and was
reported to be used in almost half of the children diag-
nosed with clinical and subclinical seizures. Lamotrigine
was the second most commonly used AED overall and
was used in about one-third of patients with clinical or
subclinical seizures. AED usage was reportedly similar in
the clinical and subclinical seizure groups in most cases,
although ethosuximide was reportedly used more often
in the subclinical seizure group as compared to the clin-
ical seizure group. Several AEDs, including lamotrigine,
levetiracetam, carbamazepine, topiramate and oxcarba-
zepine were reportedly used in one-fourth or more of
the children with clinical and/or subclinical seizures.
Vitamin B6 and steroids were the most frequently
used traditional non-AED seizure treatments. More chil-
dren in the control group were treated with steroids and
vitamin B6 as compared to the clinical seizure group.
The ketogenic diet was the third most commonly used
non-AED traditional seizure treatment. The ketogenic
diet was reportedly used more often by the seizure
groups than the control group.
Prevalence of non-traditional treatments in seizure and
control groups
Table 7 presents the reported usage prevalence of non-
traditional treatments for seizures sorted by the overall
prevalence within each treatment category. Significantly
fewer children in the clinical seizure group used vitamin
B12 and/or the gluten-free casein-free diet treatment as
compared to the control group. Both seizure groups and
the control group were reported to use all other non-
traditional supplement, drug and diet treatments with a
similar prevalence. Many treatments such as vitamin
B12, L-carnitine/acetyl-L-carnitine and magnesium were
reportedly used for approximately one-fifth of the chil-
dren reported on in this survey and approximately one-
third were treated, at least at some point, with the glu-
ten-free casein-free diet.
Differences in responders to the ARI and non-ARI support
group invitations
Very few differences were found between the responders
to the ARI and non-ARI invitations. There were no dif-
ferences in age, gender, seizure type, practitioners, diag-
nostic tests, spectrum diagnoses or medical
characteristics between responders to the ARI and non-
ARI invitations. There were a few differences in the per-
centage of children who used certain treatments
between responders to the ARI and non-ARI invitations.
Responders to the ARI invitation reported using valproic
acid (ARI 53% v Non-ARI 40%, c2 = 16.18, p < 0.0001)
and magnesium (ARI 25% v Non-ARI 13%, c2=2 0 . 1 1 ,
p < 0.0001) more often than responders to non-ARI
support group invitations.
Treatments for Clinical Seizures
For individuals that were reported to have clinical sei-
zure, the average rating of the perceived effect of each
treatment on seizures, sleep, communication, behavior,
attention and mood was obtained. These averages were
entered into a cluster analysis (discussed above in meth-
ods) to determine if certain treatments demonstrated
similar effects on seizures, sleep, communication, beha-
vior, attention and mood. The cluster analysis provided
a strong separation of the treatments into two clusters:
AED and non-AED treatment clusters (See Cluster 1
and Cluster 2 in Table 8). The overall average ratings
for seizures, sleep, communication, behavior, attention
and mood for these two clusters were obtained by aver-
aging ratings (derived from theo r i g i n a lr a t i n g s )a c r o s s
all treatments within each cluster (Figure 1). We then
determined whether there was a statistical difference in
the ratings between these groups by analyzing the rat-
ings with an ANOVA that included cluster and seizure
type (generalized seizures, partial seizures, absence sei-
zures) as the independent effects as well as the interac-
tion between these two effects. Seizure type and the
interaction between seizure type and cluster were not
significant. The effect of cluster was significant for all
ratings, including the more specific ratings for
Table 4 Developmental Characteristics by Seizure Group
Developmental
Diagnosis
Control Clinical
Seizures
Subclinical
Seizures
Autism Disorder 61% 73%
‡ 78%
‡,ns
PDD-NOS 22% 19%
ns 16%
ns,ns
Asperger Syndrome 17% 8%
† 6%
‡,ns
Developmental Profile Control Clinical
Seizures
Subclinical
Seizures
Regression 18% 28%
‡ 38%
†,ns
Plateau 7% 4%
ns 8%
ns,ns
Symptoms from infancy 34% 39%
ns 31%
ns,ns
No early symptoms 34% 29%
ns 23%
ns,ns
‡p < = 0.001; †p < = 0.0001
For each characteristic listed, statistical comparisons were made between the
clinical seizure group and the control group (superscript after the clinical
seizure percentage), the subclinical seizure group and the control group (1
st
superscript after the subclinical seizure percentage) and between the clinical
and subclinical seizure group (2
nd superscript after the subclinical seizure
percentage). Since there are 3 developmental diagnosis categories and 3
comparisons for each diagnosis category resulting in 9 comparisons. The
Bonferroni correction for developmental diagnosis portion of the table results
in an alpha of 0.05/9 = 0.0056, so we have set the alpha to p < = 0.001 to be
conservative. Since there are 4 developmental profile categories and 3
comparisons for each developmental profile category resulting in 12
comparisons. The Bonferroni correction for the developmental profile portion
of the table results in an alpha of 0.05/12 = 0.0042, so we have set the alpha
to p < = 0.001 to be conservative.
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Table S1). Overall, both AED and non-AED treatments
were perceived, on average, as making seizures better
but treatments within the AED cluster were perceived
as improving seizures significantly more than treatments
in the non-AED cluster (Figure 1). On average, treat-
ments within the AED cluster were perceived as worsen-
ing clinical factors other than seizures (i.e., sleep,
communication, behavior, attention and mood) and
treatments with the non-AED cluster were perceived as
improving clinical factors other than seizures (Figure 1).
Treatments in the non-AED cluster were perceived as
improving other clinical factors significantly better than
treatments in the AED cluster.
The first (Tier 1) cluster analysis provided evidence
for a significant separation between AED and non-AED
treatments, but did not provide information regarding
differences within each treatment cluster. In order to
determine if there were differences among treatments
within each cluster, a second set of cluster analyses
(Tier 2) were performed on the AED and non-AED
clusters separately.
AED Treatments
Cluster analysis of the AED treatments cluster resulted
in three subclusters (See AED subcluster 1, 2 and 3 in
Table 8). The overall average ratings for seizures, sleep,
communication, behavior, attention and mood for these
three subclusters were obtained by averaging ratings
(derived from the original ratings) across all treatments
within each subcluster (Figure 2A). It was then deter-
mined whether there was a statistical difference in the
ratings between these cluste r sb ya n a l y z i n gt h er a t i n g s
Table 5 Medical Characteristics by Seizure Group
Medical Diagnosis Overall Control Clinical Seizures Subclinical Seizures
Prematurity 15% 13% 15%
ns 16%
ns,ns
Cerebral Palsy 4% 1% 5%
ns 3%
ns,ns
Sensory Integration Disorder 51% 53% 48%
ns 58%
ns,ns
ADHD 31% 31% 30%
ns 31%
ns,ns
Hypotonia 24% 20% 26%
ns 27%
ns,ns
Mental Retardation 20% 7% 28%
† 18%
ns,ns
Mitochondrial disorder 10% 6% 11%
ns 17%
ns,ns
Genetic Disorder 6% 4% 7%
ns 7%
ns,ns
Renal disease 2% 2% 2%
ns 1%
ns,ns
Cardiovascular disease 2% 2% 2%
ns 2%
ns,ns
Hematological disease 1% 1% 1%
ns 1%
ns,ns
Growth
Failure-to-Thrive 14% 11% 14%
ns 15%
ns,ns
Macrocephaly 11% 9% 11%
ns 13%
ns,ns
Accelerated Growth 10% 11% 9%
ns 9%
ns,ns
Microcephaly 4% 4% 4%
ns 3%
ns,ns
Gastrointestinal Disorders
Constipation 41% 39% 42%
ns 40%
ns,ns
GERD 22% 22% 22%
ns 25%
ns,ns
Inflammation 17% 12% 18%
ns 24%
ns,ns
Dysbiosis 16% 12% 16%
ns 22%
ns,ns
LNH 4% 2% 4%
ns 7%
ns,ns
Sleep Disorders
Disrupted Sleep 44% 34% 47%
ns 53%
ns,ns
Insomnia 22% 27% 34%
ns 33%
ns,ns
Apnea 9% 8% 9%
ns 9%
ns,ns
PLMS 6% 5% 6%
ns 9%
ns,ns
†p < = 0.0001
For each characteristic listed, statistical comparisons were made between the clinical seizure group and the control group (superscript after the clinical seizure
percentage), the subclinical seizure group and the control group (1
st superscript after the subclinical seizure percentage) and between the clinical and subclinical
seizure group (2
nd superscript after the subclinical seizure percentage). There are 24 medical diagnoses and 3 comparisons for each medical diagnosis resulting
in 72 comparisons. The Bonferroni correction results in an alpha of 0.05/72 = 0.0007, so we have set the alpha to p < = 0.0001 to be conservative.
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Treatment Overall Controls Clinical Seizures Subclinical Seizures
Anti-epileptic drug treatment
Valproic acid 31% 6% 39%
† 48%
†,ns
Lamotrigine 22% 3% 27%
† 39%
†,n s
Levetiracetam 18% 1% 23%
† 31%
†,ns
Carbamazepine 18% 1% 26%
† 23%
†,ns
Topiramate 17% 1% 25%
† 22%
†,ns
Oxcarbazepine 16% 2% 22%
† 24%
†,ns
Clonazepam 12% 3% 16%
† 13%
†,ns
Phenytoin 10% 1% 13%
† 13%
†,ns
Phenobarbital 10% 2% 14%
† 11%
†,ns
Gabapentin 7% 1% 8%
† 12%
†,ns
Zonisamide 7% 0% 10%
† 12%
†,ns
Ethosuximide 4% 0% 4%
ns 10%
†,n s
Felbamate 4% 0% 5%
† 7%
†,ns
Non-antiepileptic drug treatments
Vitamin B6 19% 27% 15%
† 20%
ns,ns
Steroids 11% 21% 5%
† 14%
ns, ns
Ketogenic diet 6% 0% 7%
† 13%
†,ns
Intravenous Immunoglobulin 3% 1% 3%
ns 7%
ns,ns
Vagal Nerve Stimulator 3% 0% 4%
ns 6%
ns,ns
†p < = 0.0001
For each treatment listed, statistical comparisons were made between the clinical seizure group and the control group (superscript after the clinical seizure
percentage), the subclinical seizure group and the control group (1
st superscript after the subclinical seizure percentage) and between the clinical and subclinical
seizure group (2
nd superscript after the subclinical seizure percentage). There are 18 treatments and 3 comparisons for each treatments resulting in 54
comparisons. The Bonferroni correction results in an alpha of 0.05/54 = 0.0009, so we have set the alpha to p < = 0.0001 to be conservative.
Table 7 Non-traditional treatment usage by seizure group
Treatment Overall Controls Clinical Seizures Subclinical Seizures
Supplement treatments
Vitamin B12 24% 32% 20%
‡ 26%
ns,ns
L-Carnitine/Acetyl-L-Carnitine 21% 22% 18%
ns 29%
ns,ns
Magnesium 20% 26% 17%
ns 22%
ns,ns
Coenzyme Q10 14% 16% 12%
ns 15%
ns,ns
Glutathione 14% 14% 12%
ns 18%
ns,ns
Dimethylglycine 11% 14% 9%
ns 13%
ns,ns
Taurine 11% 10% 10%
ns 14%
ns,ns
GABA 9% 12% 8%
ns 9%
ns,ns
5-Hydroxytryptophan 8% 11% 6%
ns 9%
ns,ns
L-Carnosine 6% 5% 5%
ns 10%
ns,ns
Drug treatments
Chelation Therapy 12% 15% 10%
ns 16%
ns,ns
Hyperbaric Oxygen Therapy 7% 6% 7%
ns 10%
ns,ns
Dietary treatments
Gluten Free Casein Free Diet 31% 41% 25%
† 31%
ns,ns
Specific Carbohydrate Diet 6% 4% 6%
ns 8%
ns,ns
Atkins or Modified Atkins Diet 2% 1% 3%
ns 2%
ns,ns
‡p < = 0.001; †p < = 0.0001
For each treatment listed, statistical comparisons were made between the clinical seizure group and the control group (superscript after the clinical seizure
percentage), the subclinical seizure group and the control group (1
st superscript after the subclinical seizure percentage) and between the clinical and subclinical
seizure group (2
nd superscript after the subclinical seizure percentage). There are 15 treatments and 3 comparisons for each treatments resulting in 45
comparisons. The Bonferroni correction results in an alpha of 0.05/45 = 0.0011, so we have set the alpha to p < = 0.001 to be conservative.
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Seizure type and the interaction between seizure type
and cluster were not significant. The effect of cluster
was significant for all ratings, expect sleep and mood,
and for the more specific ratings within communication
and behavior, expect for rigidity (See Additional file 2,
Table S2).
Treatments in AED subcluster 1 were perceived as
improving seizures significantly more than the
treatments in AED subcluster 2 but the perceived effect
of the treatment in AED subcluster 3 on seizures was
not significantly different than AED subclusters 1 or 2.
Treatments in subcluster 1 were perceived to worsen
communication and attention significantly less than
treatments in AED subclusters 2 and 3 and treatments
in AED subcluster 1 were perceived to worsen behavior
and mood significantly less than AED subcluster 3 (Fig-
ure 1A; See Additional file 2, Table S2).
Since the treatments in AED subcluster 1 were per-
ceived to be more beneficial overall than treatments in
the other subclusters, the four treatments in AED sub-
cluster 1 (valproic acid, lamotrigine, levetiracetam, and
ethosuximide) were examined in greater detail. The
overall average ratings for seizures, sleep, communica-
tion, behavior, attention and mood for these four treat-
ments were obtained by averaging ratings from the
original responses for each treatment (Figure 2B). Statis-
tical differences in the ratings between these treatments
were determined using an ANOVA similar to the one
described above. Seizure type and the interaction
between seizure type and treatment were not significant.
The effect of AED treatment was significant for commu-
nication, attention and mood and one specific scale of
behavior, rigidity (See Additional file 2, Table S3).
Overall the four AED treatments (valproic acid, lamo-
trigine, levetiracetam, ethosuximide) were not perceived
to be different in their ability to improve seizures (Fig-
ure 2B; See Additional file 2, Table S3). Lamotrigine was
perceived to worsen communication, rigidity and
Table 8 Grouping of treatments for the clinical seizures
group.
Antiepileptic Drugs (Cluster 1)
AED Subcluster 1 AED Subcluster 2 AED Subcluster 3
Valproic acid
Lamotrigine
Levetiracetam
Ethosuximide
Phenytoin
Clonazepam
Carbamazepine
Oxcarbazepine
Topiramate
Gabapentin
Zonisamide
Felbamate
Phenobarbitol
Non-Antiepileptic Drugs (Cluster 2)
Non-AED Subcluster
1
Non-AED Subcluster 2 Non-AED
Subcluster 3
Ketogenic Diet
Atkins Diet
Gluten-free Casein-free
Diet
Hyperbaric Oxygen
Therapy
Vitamin B6
Intravenous
Immunoglobulin
L-Carnitine/Acetyl-L-
Carnitine
CoQ10
Vitamin B12
Dimethylglycine
Taurine
GABA
Magnesium
5HTP
L-Carnosine
Chelation
Glutathione
Specific carbohydrate
diet
Steroids
Vagus Nerve
Stimulator
Two levels of cluster analyses were performed. The first cluster analysis (Tier
1) divided treatments into anti-epileptic medication and non-antiepileptic
medications. Cluster analysis was applied to the two Tier 1 clusters separated.
Three Tier 2 subclusters were found for both initial clusters.
Figure 1 Treatments for clinical seizures cluster into anti-
epileptic drug and non-anti-epileptic drug treatments.I n
general, anti-epileptic drug treatments were perceived as improving
seizures significantly more than non-anti-epileptic drug treatments
but significantly worsening other clinical factors.
Figure 2 Rating for subclusters of anti-epileptic drug
treatments for clinical seizures. (A) Anti-epileptic drug treatment
subcluster 1 was perceived as improving seizures better than
subcluster 2 and worsened several other clinical factors less than
subclusters 2 and 3. (B) The perceived effect on seizures was not
different across the four anti-epileptic drug treatments in subcluster
1. Out of the four treatments in subcluster 1, lamotrigine appeared
to worse several other clinical factors, such as communication,
attention and mood less than other treatments.
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mood less than levetiracetam. Valproic acid was also
found to worsen mood less than levetiracetam. Ethosux-
imide did not demonstrate pair-wise differences, likely
due to the large variability in ratings for this treatment.
Non-AED Treatments
Cluster analysis of the non-AED treatments resulted in
three subclusters (See non-AED subcluster 1, 2 and 3 in
Table 8). The overall average ratings for seizures, sleep,
communication, behavior, attention and mood for these
three subclusters were obtained by averaging ratings
(derived from the original ratings) across all treatments
within each subcluster (Figure 3A). The statistical differ-
ence in the ratings between these subclusters were ana-
lyzed using an ANOVA similar to the one described
above. Seizure type and the interaction between seizure
type and subcluster were not significant. The effect of
subcluster was significant for all overall ratings and for
the more specific ratings within communication and
behavior (See Additional file 2, Table S4).
Treatments in non-AED subclusters 1 and 3 were per-
ceived to significantly improve seizures more than treat-
ments in non-AED subcluster 2. Treatments in non-
AED subcluster 1 were perceived to improve sleep,
communication, behavior, attention and mood better
than treatments in non-AED subclusters 2 and 3 (Figure
3A; See Additional file 2, Table S4).
Since treatments in non-AED subcluster 1 were per-
ceived to be more beneficial overall than treatments in
the other subclusters, the four treatments in non-AED
subcluster 1 (ketogenic diet, Atkin’s or modified Atkin’s
diet, gluten-free casein-free diet, hyperbaric oxygen ther-
apy) were examined in detail. The overall average rat-
ings for seizures, sleep, communication, behavior,
attention and mood for these four treatments were
obtained by averaging ratings from the original
responses for each treatment (Figure 3B). Statistical dif-
ferences in the ratings between these treatments were
determined using an ANOVA similar to the one
described above. Seizure type and the interaction
between seizure type and treatment were not significant.
The effect of treatment was significant for seizures and
behavior, including the subscales of behavior (See Addi-
tional file 2, Table S5).
The ketogenic diet was perceived to significantly
improve seizures more than the gluten-free casein-free
diet and hyperbaric oxygen therapy, and gluten-free
casein-free diet was perceived to improve seizures signif-
icantly more than hyperbaric oxygen therapy (Figure 3B;
See Additional file 2, Table S5). Both the gluten-free
casein-free diet and the ketogenic diet were found to
improve behavior significantly more than hyperbaric
oxygen therapy.
Treatments for Subclinical Seizures
For individuals reported to have subclinical seizure, the
average rating of the perceived effect of each treatment
on seizures, sleep, communication, behavior, attention
and mood was calculated and entered into a cluster
analysis to determine whether certain treatments
demonstrated similar effects on sleep, communication,
behavior, attention and mood. The cluster analysis
provided a strong separation of the treatments into
two clusters: AED and non-AED treatment clusters
(See Cluster 1 and Cluster 2 in Table 9). The overall
average ratings for sleep, communication, behavior,
attention and mood for these two clusters were
obtained by averaging ratings (derived from the origi-
nal ratings) across all treatments within each cluster
(Figure 4). Statistical differences in the ratings between
these clusters were determined by analyzing the ratings
with an ANOVA which included cluster and subclini-
cal seizure type (typical Landau-Kleffner syndrome,
atypical Landau-Kleffner syndrome, subclinical epilepti-
form discharges) as the independent effects as well as
the interaction between these two effects. Subclinical
s e i z u r et y p ea n dt h ei n t e r a c t i o nb e t w e e ns e i z u r et y p e
and cluster were not significant. The effect of cluster
was significant for all ratings, including the more spe-
cific ratings for communication and behavior (See
Additional file 2, Table S6).
Figure 3 Rating for subclusters of non-anti-epileptic drug
treatments for clinical seizures. (A) Non-anti-epileptic drug
treatment subcluster 1 was perceived as improving seizures better
than subcluster 2 and improving several other clinical factors more
than subclusters 2 and 3. (B) The ketogenic diet was perceived to
improve seizures more than the gluten-free-casein-free diet and
hyperbaric oxygen treatment. Other clinical factors were not
perceived to differ significantly between these four treatments
except for behavior, which was perceived to be significantly worse
with hyperbaric oxygen treatment as compared to the ketogenic
diet and the gluten-free-casein-free diet.
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were perceived to be worsened by AED treatments and
improved by non-AED treatments (Figure 4; See Addi-
tional file 2, Table S6). The cluster analysis was applied
to these two clusters separately but the cluster analysis
demonstrated very low pseudo-F and pseudo-t values,
indicating that there was no strong subclustering.
Adverse Effects
Although the survey was designed to examine the most
salient effects of treatments related to ASD, all treat-
ments can have adverse effects and it is important to
know the likelihood of experiencing such adverse effects
when recommending a treatment. The adverse effects
for the four most effective AED (valproic acid, lamotri-
gine, levetiracetam, ethosuximide) and non-AED (keto-
genic diet, Atkin’s or modified Atkin’s diet, gluten free
casein free diet and hyperbaric oxygen therapy) treat-
ments for clinical seizures were reviewed. The survey
asked the parents to state the specific adverse effects, up
to three, associated with each treatment and to rate
each of the adverse effects as mild, moderate or severe.
The rates of reporting one, two or three adverse effects
regardless of the severity and for severe adverse effects
only for each treatment are presented in Table 10. In
general, AED treatments, except for ethosuximide, were
reported to have a higher rate of adverse effects as com-
pared to non-AED treatments, especially with respect to
severe adverse effects. Ethosuximide, an AED treatment,
and the ketogenic diet, a non-AED treatment, demon-
strated slightly higher rateso fa d v e r s ee f f e c t sa sc o m -
pared to the non-AED treatment besides the ketogenic
diet.
The rates for specific adverse effects are outlined in
Table 11-12 for the eight treatments described above.
AED treatments (Table 11) demonstrated a higher rate
of mood and behavioral changes as compared to non-
AED treatments (Table 12). AED treatments and the
ketogenic and Atkin’s/modified Atkin’s diets tended to
result in drowsiness, tiredness or fatigue. The ketogenic
diet also appeared to result in a high rate of constipa-
tion or diarrhea.
Discussion
This study examined the clinical characteristics of chil-
dren with ASD and clinical and/or subclinical seizures,
their management, and parental perception of effective-
ness of traditional treatments for seizures and non-tradi-
tional treatments using an on-line survey. A survey that
gathered information about children with ASD without
seizures was also used to gather control data. The sur-
veys were advertized on ASD-related websites. Both tra-
ditional treatments for seizures and non-traditional ASD
treatments were considered and the perceived effective-
ness of these treatments on seizures, sleep, communica-
tion, behavior, attention and mood was queried. The
perceived effectiveness of treatments was analyzed for
individuals with clinical and subclinical seizures sepa-
rately. One of the most important findings of this study
was that certain AED and non-AED treatments were
perceived as improving seizures while also improving, or
at least not worsening, other clinical factors that are
important in children with ASD. We will address speci-
f i ca s p e c t so ft h i ss t u d y ’s findings in separate sections
below.
Characteristics of Children with ASD and Seizures
The proportion of male children in both the seizures
and control survey was exactly the same, 77%, and con-
sistent with other reports of the portion of males in the
general ASD population [19]. Children with ASD and
both clinical and subclinical seizures were more likely to
have a diagnosis of Autism Disorder, and less likely to
have a diagnosis of Asperger syndrome, than the control
children. Children with ASD and clinical seizures, but
not subclinical seizures, were more likely to have mental
retardation than control children but other medical con-
ditions were not different between the seizure and
Table 9 Grouping of treatments for subclinical seizures
using cluster analysis.
Treatments for Subclinical Seizures
Cluster 1 Cluster 2
Valproic acid
Levetiracetam
Lamotrigine
Carbamazepine
Oxcarbazepine
Topiramate
Vitamin B6
Steroids
L-Carnitine/Acetyl-L-Carnitine
CoQ10
Vitamin B12
Taurine
Magnesium
Chelation
Glutathione Gluten-free Casein-free Diet
Ketogenic Diet/Atkin’s Diet
A cluster analysis divided treatments into anti-epileptic drug treatments and
non-antiepileptic drug treatments. Cluster analysis was applied to clusters 1
and 2 separately but no subclusters were evident.
Figure 4 Treatments for subclinical seizures cluster into anti-
epileptic drug and non-anti-epileptic drug treatments.I n
general, anti-epileptic drug treatments were perceived as worsening
clinical factors while non-anti-epileptic drug treatments appeared to
improve clinical factors.
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and clinical seizures have more severe cognitive difficul-
ties as compared to children with ASD without seizure,
consistent with previous studies [20-22]. Children with
ASD and both clinical and subclinical seizures are more
likely to have regression as compared to control chil-
dren, consistent with previous studies [23]. It is impor-
tant to point out that despite the higher rate of
regression in children with ASD and either clinical or
subclinical seizures, the majority of such children in
these groups did not have regression. Thus, it is impor-
tant to approach children with both regressive and non-
regressive ASD with a similar index of suspicion when
considering a workup for seizures.
Management and Diagnosis of Children with ASD and
Seizures
Overall, for children with ASD in general, pediatricians
managed medical and developmental issues. A child
neurologist managed the medical and developmental
issues of the majority of children with ASD and either
clinical and/or subclinical seizures. The medical and
developmental aspects of the child were managed, in
part, by a doctor affiliated with Defeat Autism Now! in
Table 10 Rates of adverse effects regardless of the severity and the rate of severe adverse effects for treatments
perceived to be most effective.
Number of Adverse Effects Number of Severe Adverse Effects
Treatment One Two Three One Two Three
Valproic Acid 48% 25% 11% 15% 4% 5%
Lamotrigine 34% 19% 12% 16% 3% 1%
Levetiracetam 43% 19% 10% 16% 2% 3%
Ethosuximide 26% 7% 7% 7% 0% 4%
Ketogenic Diet 27% 13% 4% 8% 0% 2%
Atkin’s Diet/Modified Atkin’s Diet 15% 0% 0% 0% 0% 0%
Gluten-free Casein-free Diet 6% 2% 1% 3% 1% 0%
Hyperbaric Oxygen Therapy 10% 6% 4% 6% 0% 2%
Table 11 Rates of specific adverse effects for the antiepileptic drug treatments reported to be most effective
Adverse Effects Valproic Acid Lamotrigine Levetiracetam Ethosuximide
Mood Instability or Anger 10% 10% 21% 4%
Behavioral Change 5% 3% 8% 0%
Drowsiness/tiredness/fatigue 10% 4% 8% 7%
Change in appetite or weight 11% 2% 3% 7%
Increase in seizures 2% 5% 4% 7%
Constipation or diarrhea 3% 2% 1% 0%
Sleep disruption 4% 5% 3% 4%
Inattention or confusion 4% 3% 4% 0%
Rash or allergic reaction 1% 7% 1% 0%
Hyperactivity 4% 3% 3% 4%
Nausea and/or vomiting 2% 3% 1% 4%
Ataxia, tremor or dizziness 6% 3% 1% 0%
Unusual infection 1% 0% 1% 0%
Movement disorder 1% 2% 2% 0%
Anxiety 1% 1% 2% 0%
Headache 1% 3% 0% 0%
Hair loss 3% 1% 0% 0%
Visual disturbances 0% 1% 1% 0%
Speech disturbance 3% 4% 4% 0%
Enuresis 1% 0% 1% 0%
Other 6% 0% 2% 4%
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from this data that multiple practitioners, in general,
manage children with ASD, presumably due to the com-
plexity of this disorder.
The great majority of children (i.e., > 88%) with clini-
cal and subclinical seizures were diagnosed and mana-
ged, at least in part, by a child or adult neurologist. This
is an encouraging finding, but it is important for all chil-
dren with any type of seizure activity to be managed by
an expert in seizures such as a neurologist or epileptolo-
gist. Over half of the control children with ASD were
never evaluated for seizures. Our recent study on subcli-
nical discharges demonstrated that many of the children
with such discharges have no specific symptoms except
for delays in language development and features of ASD
and/or attention deficit [24]. Thus, it is important to
keep a high index of suspicion for seizures, especially
subclinical seizures, in children with ASD since the
symptoms of subclinical seizures can be subtle [24]. In
addition, partial complex seizures, especially that origi-
nate in the temporal or frontal lobes can present as
complex behaviors and automatisms that may be diffi-
cult to differentiate ASD behaviors [25-30]. This may be
true especially in non-verbal and/or non-communicative
children who cannot express symptoms and in whom
paradoxical symptoms, such as speech arrest, cannot be
easily observed.
The majority of children with ASD and seizures
underwent a routine EEG as a diagnostic test for their
clinical and/or subclinical seizure disorder while signifi-
cantly fewer children with ASD and clinical seizures had
an overnight and ambulatory EEG as compared to chil-
dren with subclinical seizures. Of course, many of the
subclinical seizure disorders require an overnight EEG
to diagnose, so this is not unexpected. Of the children
with clinical and subclinical seizures, 17% and 10% of
them did not have any diagnostic test for diagnosis,
respectively. This is concerning, especially for subclinical
seizures, since ASD behaviors, especially staring, can be
mistaken for subtle seizure activity.
Treatments for Clinical Seizures
One of the most important findings of this study was
that AED treatments, as compared to non-AED treat-
ments, were perceived by parents as improving seizures
but, as a group, they were perceived as worsening other
clinical factor (i.e., sleep, communication, behavior,
attention and mood) for children with ASD and clinical
seizures. However, four AED treatments (valproic acid,
lamotrigine, levetiracetam and ethosuximide) were per-
ceived by parents to improve seizures and not worsen
other clinical factors. Clearly AEDs are important for
treating clinical seizures in children with ASD but do
not appear to be rated as helpful for treating other
comorbid clinical factors associated with ASD such as
communication, behavior and mood. It is somewhat sur-
prising that AEDs such as valproic acid and lamotrigine
were not perceived to have a more positive effect on
mood as both of these medications are considered
mood stabilizers [6].
Interestingly, most AED and non-AED treatments
examined were perceived to improve seizures or other
clinical factors, but not both. The exception were four
non-AED treatments (ketogenic diet, Atkin’so rm o d i -
fied Atkin’s diet, gluten free casein free diet and hyper-
baric oxygen therapy), which were perceived to improve
both seizures and other clinical factors. ASD has been
suggested to be associated with cortical hyperexcitability
[5]. AEDs exert their effect by reducing cortical excit-
ability [31]. The fact that some of the key symptoms
Table 12 Rates of specific adverse effects for the non-
antiepileptic drug treatments reported to be most
effective
Adverse Effects Ketogenic
Diet
Atkin’s
or
modified
Atkin’s
Diet
Gluten-
free
Casein-
free
Diet
Hyperbaric
Oxygen
Therapy
Mood Instability or
Anger
0% 0% 2% 4%
Behavioral Change 2% 0% 1% 2%
Drowsiness/tiredness/
fatigue
8% 0% 1% 0%
Change in appetite or
weight
2% 10% 2% 0%
Increase in seizures 4% 0% 0% 0%
Constipation or
diarrhea
12% 5% 3% 0%
Sleep disruption 2% 0% 0% 4%
Inattention or
confusion
0% 0% 1% 2%
Rash or allergic
reaction
0% 0% 0% 0%
Hyperactivity 2% 0% 0% 0%
Nausea and/or
vomiting
2% 0% 0% 0%
Ataxia, tremor or
dizziness
0% 0% 0% 0%
Unusual infection 0% 0% 0% 4%
Movement disorder 2% 0% 0% 0%
Anxiety 0% 0% 0% 0%
Headache 0% 0% 0% 0%
Hair loss 0% 0% 0% 0%
Visual disturbances 0% 0% 0% 0%
Speech disturbance 0% 0% 0% 0%
Enuresis 0% 0% 0% 0%
Other 10% 0% 0% 2%
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are perceived to be improved by reducing cortical
hyperexcitability suggests that the cortical hyperexcit-
ability associated with seizures is not a major part of the
neuropathology leading to the cognitive features asso-
ciated with ASD, at least in the subgroup of children
with clinical seizures. Interestingly, although the cortical
hyperexcitability associated with ASD has been attribu-
ted to an inhibitory deficit [5], many of the AEDs
thought to target inhibitory gamma-aminobutyric acid
mechanisms were not the ones perceived to be most
effective in this population.
Many parents reported using non-AED treatments for
their children with ASD and seizures. Interestingly, sev-
eral non-AED treatments were perceived as efficacious
in treating both seizures and other clinical factors. One
treatment, the ketogenic diet, was perceived as very
effective for improving seizures as compared to other
AED and non-AED treatments and was perceived as
having favorable effects on sleep, communication, beha-
vior, attention and mood. The ketogenic diet is well
known to be effective in drug resistant epilepsy [32] and
has been reported to be effective in the treatment of
ASD [33]. The effectiveness of the ketogenic diet for the
treatment of both ASD and seizures could be through
several mechanisms. The ketogenic diet has been shown
to be effective for improving mitochondrial function
[34] and oxidative stress [35], two biological mechan-
isms believed to underlie the neuropathology associated
with both ASD [11,36,37] and seizures [13]. The rate of
adverse effects, especially for multiple adverse effects,
was lower for ketogenic diet as compared to the AED
treatments and the specific adverse effect profile was
different with lower rates of adverse behavior or mood
as compared to AED treatments. The Atkin’so rm o d i -
fied Atkin’s diet which, like the ketogenic diet, promotes
ketosis and limits carbohydrate metabolism, was also
perceived as effective at improving seizures with a favor-
able adverse effect profile and has been reported to have
similar effectiveness at treating epilepsy as the ketogenic
diet [32]. Of course the ketogenic diet, as well as any
dietary treatment, can result in adverse effects, such as
severe acidosis, which might dangerous in children with
ASD, particularly those with metabolic conditions such
as mitochondrial disorders. Thus, the ketogenic diet as
well as other therapies should be managed by a practi-
tioner with considerable experience with such therapies.
Clearly these treatments require further study in indivi-
duals with ASD and seizures.
Treatments for Subclinical Seizures
For the subclinical seizure group, AED treatments were
not perceived to significantly improve cognitive and
behavioral factors related to ASD. This was somewhat
o fas u r p r i s ea ss o m eo ft h eA E D sr e p o r t e dt ob eu s e d
in this group have been associated with improvement in
language, attention and behavior in some children with
subclinical seizures, particularly those with Landau-
Kleffner syndrome [38] and subclinical epileptiform dis-
charges [24]. The ketogenic diet and steroids were in
the non-AED treatment cluster that was rated as show-
ing improvement in communication and behavior,
thereby verifying previous studies [38,39]. Overall, the
ketogenic diet and steroids were perceived as having a
similar benefit as compared to several other non-AED
treatments (see Table 8 and Figure 3), but the perceived
improvement attributed to treatments within this clus-
ter, on average, was not particularly high. This is consis-
tent with the very variable effectiveness of treatments
for subclinical epileptiform discharges [38]. Most likely,
a more detailed approach to analyzing this group of
patients by, perhaps, examining individual patient-to-
patient variability, will provide more information regard-
ing which patients respond to treatment. A larger num-
ber of respondents would also assist in providing more
accurate information.
Limitations
This study was designed to obtain general parental
impressions regarding the effectiveness of seizure speci-
fic treatments and general alternative ASD treatments
on seizures and other clinical factors. In this study we
consider each treatment in isolation as if it was given in
a controlled manner and any resulting effects could be
directly related to the treatment. However, many chil-
dren with ASD are prescribed multiple treatments and
many families initiate and/or discontinue treatments
without advice from the practitioner that is managing
their child. Despite this limitation, some clear perceived
differences between treatments were evident in this
survey.
It should be mentioned that the relation to the indivi-
dual being reported was not queried, so it is possible
that other caretakers of a child with ASD could have
completed the survey instead of the parents. The infor-
mation obtained was only the perception of the parents
and was not documented by trained professionals. This
may have limited the validity of the information in sev-
eral ways. First, instruments used to diagnose ASD vary
from clinic-to-clinic and it is possible that the ASD
diagnosis was not made using any standardized tool
since we did not verify the diagnosis. However, the over-
whelming majority of parents reported that either a
child or adult neurologist managed their ASD child if
they had clinical seizures, subclinical epileptiform dis-
charges or seizure-like activity and the majority of the
parents of children with ASD who completed the con-
trol survey reported that the a pediatrician or
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ment. Thus, the parents who responded to this survey
had adequate professional advice on which to base their
report.
This study is subject several other limitations
including potential bias of the responders. Most con-
cerning is that individuals who tend to use non-tradi-
tional therapies may be critical of traditional drug
treatments due to adverse effects [10]. So, relative
rankings of one AED vs. another may be reasonable,
but the effectiveness of AEDs may be somewhat
under-reported relative to non-AED treatments. In
addition, since medical information was obtained
from parents, not medical records, this information
could contain inaccuracies. Furthermore, the diagno-
sis of the subclinical seizures types can be very vari-
able from practitioner-to-practitioner and some
individuals may be told that an EEG is normal if it
contains paroxysmal discharges that are considered to
be not clinically significant by the practitioner.
Despite these limitations, the information gained from
this survey provides important insight into which
treatments should be further evaluated for individuals
with ASD and clinical seizures.
Only 6% of children, overall, were reported to have
genetic conditions, whichi sa tt h el o w e re n do fs o m e
estimates of the number of children with ASD who have
genetic conditions [40]. This suggests that we may have
under sampled this subgroup of children with ASD.
Conclusions
Parents of children with ASD report that AEDs improve
seizure control but worsen other clinical factors in indi-
viduals with ASD and clinical seizures. Particular AEDs,
including valproic acid, lamotrigine, levetiracetam, are
reported to provide the best seizure control and worsen
sleep, communication, behavior, attention and mood the
least out of all of the AEDs in children with ASD and
clinical seizures. In individuals with ASD and clinical
seizures, non-AED treatments, in general, were reported
to improve sleep, communication, behavior, attention
and mood but improve seizures significantly less than
AED treatments. Particular non-AED treatments, such
as the ketogenic diet, were perceived to improve both
seizures and other cognitive and behavioral factors in
individuals with ASD and clinical seizures. Although
this survey-based method only provides information of
the parents’ perceptions of effectiveness, this informa-
tion is important for selecting seizure treatments in
individuals with ASD that should undergo further
evaluation.
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